Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | CHIT1 | Q13231 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA4 | P22748 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864632 | 1.00 | FOLH1 (0.45) | FOLH1CHIT1DPP4S1PR1DPP7 | |
| SCHEMBL1079200 | 1.00 | FOLH1 (0.45) | FOLH1CHIT1DPP4S1PR1DPP7 | |
| SCHEMBL15904929 | 1.00 | FOLH1 (0.45) | FOLH1CHIT1DPP4S1PR1DPP7 | |
| SCHEMBL17119211 | 1.00 | FOLH1 (0.45) | FOLH1CHIT1DPP4S1PR1DPP7 | |
| Hydrochloric Acid SCHEMBL31226505 | 0.99 | FOLH1 (0.44) | FOLH1CHIT1DPP4S1PR1DPP7 | |
| SCHEMBL436094 | 0.94 | LMNA (0.45) | FOLH1CHIT1DPP4S1PR1CA1 | |
| SCHEMBL23627788 | 0.93 | HSD17B10 (0.44) | FOLH1CHIT1DPP4 | |
| SCHEMBL12974377 | 0.93 | FOLH1 (0.41) | FOLH1CHIT1DPP4SIGMAR1 | |
| SCHEMBL4098689 | 0.93 | HSD17B10 (0.44) | FOLH1CHIT1DPP4 | |
| SCHEMBL12261650 | 0.93 | FOLH1 (0.41) | FOLH1CHIT1DPP4S1PR1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10806808-B2 | Systems and methods for determining optimum patient-specific antibody dose for tumor targeting | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-10-20 | — | — | US | claimed |
| EP-3297669-B1 | SYSTEMS AND METHODS FOR DETERMINING OPTIMUM PATIENT-SPECIFIC ANTIBODY DOSE FOR TUMOR TARGETING | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-05-06 | — | — | EP | claimed |
| US-20180133350-A1 | SYSTEMS AND METHODS FOR DETERMINING OPTIMUM PATIENT-SPECIFIC ANTIBODY DOSE FOR TUMOR TARGETING | MEMORIAL SLOAN KETTERING CANCER CENTER | 2018-05-17 | — | — | US | claimed |
| EP-3297669-A1 | SYSTEMS AND METHODS FOR DETERMINING OPTIMUM PATIENT-SPECIFIC ANTIBODY DOSE FOR TUMOR TARGETING | Memorial Sloan-Kettering Cancer Center (US) | 2018-03-28 | — | — | EP | claimed |
| WO-2016191186-A1 | SYSTEMS AND METHODS FOR DETERMINING OPTIMUM PATIENT-SPECIFIC ANTIBODY DOSE FOR TUMOR TARGETING | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2016-12-01 | — | — | WO | claimed |
| US-6911457-B2 | Imaging probes and methods for using the probes in diagnostic imaging processes and other imaging processes to determine physiological functions. | CARBOMER, INC. (US) | 2005-06-28 | — | — | US | claimed |
| US-20030207823-A1 | Novel diabetes imaging probes | CARBOMER, INC. | 2003-11-06 | — | — | US | claimed |
| WO-2003086563-A2 | DIABETES IMAGING PROBES | CARBOMER, INC. (US) | 2003-10-23 | — | — | WO | claimed |
| US-12486302-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2025-12-02 | — | — | US | disclosed |
| US-12440833-B2 | Sample containers adapted for acoustic ejections and sample preservation and methods thereof | LABCYTE INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-3983020-B1 | AGENTS FOR CLEAVING LABELS FROM BIOMOLECULES IN VIVO | TAGWORKS PHARMACEUTICALS B V (NL) | 2024-06-26 | — | — | EP | disclosed |
| WO-2023165987-A1 | PRECURSOR MARKERS AND RADIOTRACERS WITH THREE OR MORE TARGETING VECTORS FOR THERANOSTICS USED IN NUCLEAR MEDICINE | Atoms for Cure GmbH (DE) | 2023-09-07 | — | — | WO | disclosed |
| US-20230235087-A1 | ANTI-GD2 SADA CONJUGATES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER | 2023-07-27 | — | — | US | disclosed |
| WO-2023118195-A1 | FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS | Atoms for Cure GmbH (DE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2003086563-A2 | DIABETES IMAGING PROBES | CARBOMER, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030059368-A1 | Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products | BIOPAL, INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2002062397-A2 | CHELATES OF METALS WHICH CAN BE ACTIVATED BY NEUTRONS AND THEIR USE FOR THE MEASUREMENT OF LABELED SPECIMENS | BIOPHYSICS ASSAY LABORATORY, INC. (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-0523572-B1 | Nuclear magnetic resonance imaging agent | NIHON MEDIPHYSICS CO LTD (JP) | 1996-10-02 | — | — | EP | disclosed |
| US-5271929-A | Nuclear magnetic resonance imaging agent comprising a di-aldehyde complex | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1993-12-21 | — | — | US | disclosed |
| EP-0523572-A1 | Nuclear magnetic resonance imaging agent | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1993-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486302-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | FOLH1 526/4885CHIT1 2780/4885DPP4 167/4885 |
| US-20030207823-A1 | Novel diabetes imaging probes | IAPP, GPR119, DPP4 | FOLH1 716/4885CHIT1 1632/4885DPP4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.